Nitric oxide modulates tissue plasminogen activator release in normotensive subjects and hypertensive patients

Hypertension. 2007 Apr;49(4):878-84. doi: 10.1161/01.HYP.0000260471.16113.d8. Epub 2007 Mar 5.

Abstract

We evaluated the possible role of NO in modulating tissue plasminogen activator (t-PA) release in the forearm microcirculation of normotensive subjects and hypertensive patients. Essential hypertensive patients are characterized by endothelial dysfunction because of a reduced NO availability and also show an impaired t-PA release. In healthy volunteers and essential hypertensive patients, we studied local t-PA release and forearm blood flow changes (strain-gauge plethysmography) induced by intrabrachial administration of acetylcholine (0.45 and 1.5 microg/100 mL/min) and of sodium nitroprusside (0.5 and 1.0 microg/100 mL/min), an endothelium-dependent and -independent agonist, respectively. Acetylcholine was also repeated in the presence of intra-arterial infusion of the NO synthase inhibitor N(G)-monomethyl-l-arginine (100 microg/100 mL/min). In normotensive subjects, vasodilation to acetylcholine was blunted by N(G)-monomethyl-l-arginine. In these subjects, acetylcholine infusion induced a significant, dose-dependent increase in net forearm t-PA release. N(G)-monomethyl-l-arginine significantly reduced basal t-PA release, as well as acetylcholine-induced t-PA release. In essential hypertensive patients, vasodilation to acetylcholine was reduced as compared with controls and resistant to N(G)-monomethyl-l-arginine. In contrast to what was observed in healthy control subjects, in hypertensive patients, acetylcholine had no effect on t-PA release. Similarly, N(G)-monomethyl-l-arginine failed to modify either the tonic or the agonist-induced t-PA release. Both tonic and agonist-induced release of NO are directly involved in t-PA release by endothelial cells. Essential hypertension, characterized by a reduction in tonic and stimulated NO availability, is also associated with impaired capacity of t-PA release, suggesting a major role of impaired NO availability in worsening both vasodilation and t-PA release.

MeSH terms

  • Acetylcholine / administration & dosage
  • Acetylcholine / pharmacology
  • Adult
  • Aged
  • Brachial Artery
  • Enzyme Inhibitors / pharmacology
  • Forearm / blood supply
  • Humans
  • Hypertension / metabolism*
  • Injections, Intra-Arterial
  • Male
  • Middle Aged
  • Nitric Oxide / metabolism*
  • Nitric Oxide Donors / administration & dosage
  • Nitric Oxide Donors / pharmacology
  • Nitric Oxide Synthase / antagonists & inhibitors
  • Nitroprusside / administration & dosage
  • Nitroprusside / pharmacology
  • Plasminogen Activator Inhibitor 1 / metabolism
  • Regional Blood Flow
  • Tissue Plasminogen Activator / metabolism*
  • Vasodilator Agents / administration & dosage
  • Vasodilator Agents / pharmacology
  • omega-N-Methylarginine / pharmacology

Substances

  • Enzyme Inhibitors
  • Nitric Oxide Donors
  • Plasminogen Activator Inhibitor 1
  • Vasodilator Agents
  • Nitroprusside
  • omega-N-Methylarginine
  • Nitric Oxide
  • Nitric Oxide Synthase
  • Tissue Plasminogen Activator
  • Acetylcholine